Etomidate Versus Propofol in CABG Surgery

Part of paid clinical trials in Hartford, Connecticut.

Sponsor
Hartford Hospital
Study ID
NCT06068764
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Coronary Artery Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Etomidate — DRUG
    The type of general anesthesia induction agent for CABG surgery
  • Propofol — DRUG
    The type of general anesthesia induction agent for CABG surgery

Study Details

The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this study is to determine whether patients receiving etomidate or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the intraoperative and postoperative periods. To achieve this goal, participants who are scheduled for CABG surgery will be randomly assigned to receive either etomidate or propofol as the principal hypnotic agent. The researchers will then compare the effects of these two anesthesia induction agents on various factors, including the need for hemodynamic support, hemodynamic stability, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital length of stay. Additionally, they will assess whether there are disparities in mortality rates and readmission rates within a 6-month timeframe after the surgery. By comparing the outcomes between the two groups, the study aims to provide valuable insights into the potential differences in vasopressor or ionotropic agent requirements between etomidate and propofol. This information can help inform clinical decision-making and potentially optimize anesthesia management strategies for patients undergoing CABG surgery.

Key Dates

Start date
Dec 5, 2023
Status verified
Dec 2023
Primary completion
Dec 31, 2025
Completion
Aug 31, 2026

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Etomidate
    Etomidate as the principal hypnotic agent in a single bolus dose of 0.2-0.3 mg/kg along with 250mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
  • Active Comparator: Propofol
    Propofol as the principal hypnotic agent in a single bolus dose of 50mg of propofol along with 250 mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.

Primary Outcome Measure

Vasopressors dose expressed by Noradrenaline Equivalent dose [μg/kg/min] [ Time Frame: 30 minutes after induction, last 30 minutes of post bypass period, and first 24 hours post procedure. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Hartford HospitalHartfordConnecticut06106
Aseel Walker, MD
[email protected]
860-972-1778
Joseph Hinchey, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Hartford, CT

By research site
Hartford Hospital· Hartford, CT

Related Studies